NSE filing, NSE: REMUS. Summary written from the filing by ALFA Finder's alert engine.
Remus Pharmaceuticals Ltd: key numbers
- Share price
- ₹843.35
- Market cap
- ₹993.8 Cr
- Revenue (annual)
- ₹853.6 Cr
- Net profit (annual)
- ₹36.99 Cr
- P/E (TTM)
- 26.9×Sector 45.9×
- Promoter holding
- 70.95%
- FII holding
- 5.10%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Remus Pharmaceuticals Ltd
All →Remus Pharmaceuticals Other Announcement
Remus Pharmaceuticals filed its Reg 76 Reconciliation of Share Capital Audit Report for Q1 FY2027. It is a routine depository-compliance certificate with no transaction or business event.
Remus Pharmaceuticals Annual General Meeting
Remus Pharmaceuticals Limited shareholders approved the migration of equity shares from the NSE Emerge platform to the main boards of NSE and BSE.
Remus Pharmaceuticals Annual General Meeting
Remus Pharmaceuticals held its 11th Annual General Meeting on September 29, 2026. Shareholders discussed financial results, dividend declaration, and director appointments.
Remus Pharmaceuticals Dividend
Remus Pharmaceuticals Limited has fixed September 22, 2026, as the record date for determining shareholder entitlement to a final dividend of Rs. 0.50 per share.
Remus Pharmaceuticals Annual General Meeting
Remus Pharmaceuticals Limited has issued a postal ballot notice seeking shareholder approval for the migration of its equity shares from the NSE Emerge platform to Main Board.
Remus Pharmaceuticals Merger & Restructuring
Remus Pharmaceuticals will incorporate a new subsidiary in the Dominican Republic for pharmaceutical distribution. The company will hold at least 51% of its share capital.
Other management change announcements
All →NHPC Management Change
NHPC disclosed that Executive Director Shri Vivek Dwivedi's tenure ends on superannuation, effective October 31, 2026. The filing reports no replacement or financial impact.
BEML Management Change
BEML Limited informed exchanges that two senior executives, including the Executive Director (Offg.) Aparup Sinha, ceased office on superannuation effective 31 October 2026. No monetary value is involved.
Jay Jalaram Technologies Management Change
Jay Jalaram Technologies appointed Varjivandas Nathuram Thakkar as Non-Executive Non-Independent Director and Vishnu Harjivanbhai Thaker as Company Secretary. Both appointments are effective 31 October 2026.
Chennai Petroleum Corporation Management Change
Chennai Petroleum's Director (Operations) P. Kannan ceased on superannuation, effective 31 October 2026. S. G. Venkatesh takes additional charge from 1 November 2026.
GAMCO Management Change
GAMCO appointed Jayshri Tulsyan as Non-Executive Independent Director for 24 months, effective October 31, 2026. Ayushi Khaitan resigned as Non-Executive Non-Independent Director, citing personal reasons.
Dhampur Bio Organics Management Change
Dhampur Bio Organics' VP Financial Planning and Analysis, Harmeet Singh, resigned, effective October 31, 2026. It is a senior management departure.